Calcagnile M, Jeguirim I, Tredici S, Damiano F, Alifano P
Antibiotics (Basel). 2023; 12(3).
PMID: 36978366
PMC: 10044227.
DOI: 10.3390/antibiotics12030499.
Lenz K, Klosterman K, Mukundan H, Kubicek-Sutherland J
Toxins (Basel). 2021; 13(5).
PMID: 34065929
PMC: 8150546.
DOI: 10.3390/toxins13050347.
Chen Q, Lu W, Zhou D, Zheng G, Liu H, Qian C
Pol J Microbiol. 2021; 69(3):349-356.
PMID: 33574864
PMC: 7810118.
DOI: 10.33073/pjm-2020-038.
Shimizu T, Miyoshi-Akiyama T, Ogura K, Murata S, Ishige S, Kai K
Antimicrob Agents Chemother. 2020; 64(10).
PMID: 32718959
PMC: 7508591.
DOI: 10.1128/AAC.01180-20.
Kundukad B, Schussman M, Yang K, Seviour T, Yang L, Rice S
Sci Rep. 2017; 7(1):4783.
PMID: 28684849
PMC: 5500524.
DOI: 10.1038/s41598-017-05178-3.
Differential Contribution of the Aryl-Hydrocarbon Receptor and Toll-Like Receptor Pathways to IL-8 Expression in Normal and Cystic Fibrosis Airway Epithelial Cells Exposed to .
Roussel L, LaFayette S, Nguyen D, Baglole C, Rousseau S
Front Cell Dev Biol. 2017; 4:148.
PMID: 28066767
PMC: 5177610.
DOI: 10.3389/fcell.2016.00148.
In vitro and in vivo activity of EDTA and antibacterial agents against the biofilm of mucoid Pseudomonas aeruginosa.
Liu Z, Lin Y, Lu Q, Li F, Yu J, Wang Z
Infection. 2016; 45(1):23-31.
PMID: 27189338
DOI: 10.1007/s15010-016-0905-z.
Mass Spectrometry Analysis of Pseudomonas aeruginosa Treated with Azithromycin.
Phelan V, Fang J, Dorrestein P
J Am Soc Mass Spectrom. 2015; 26(6):873-7.
PMID: 25801585
PMC: 4425625.
DOI: 10.1007/s13361-015-1101-6.
Analysis of bacterial biofilms using NMR-based metabolomics.
Zhang B, Powers R
Future Med Chem. 2012; 4(10):1273-306.
PMID: 22800371
PMC: 3564560.
DOI: 10.4155/fmc.12.59.
Comparison of the virulence of exopolysaccharide-producing Prevotella intermedia to exopolysaccharide non-producing periodontopathic organisms.
Yamanaka T, Yamane K, Furukawa T, Matsumoto-Mashimo C, Sugimori C, Nambu T
BMC Infect Dis. 2011; 11:228.
PMID: 21864411
PMC: 3182146.
DOI: 10.1186/1471-2334-11-228.
Antibiotics as signal molecules.
Romero D, Traxler M, Lopez D, Kolter R
Chem Rev. 2011; 111(9):5492-505.
PMID: 21786783
PMC: 3173521.
DOI: 10.1021/cr2000509.
Mechanisms of action and clinical application of macrolides as immunomodulatory medications.
Kanoh S, Rubin B
Clin Microbiol Rev. 2010; 23(3):590-615.
PMID: 20610825
PMC: 2901655.
DOI: 10.1128/CMR.00078-09.
N-acetylcysteine inhibit biofilms produced by Pseudomonas aeruginosa.
Zhao T, Liu Y
BMC Microbiol. 2010; 10:140.
PMID: 20462423
PMC: 2882372.
DOI: 10.1186/1471-2180-10-140.
Role of macrolide therapy in chronic obstructive pulmonary disease.
Martinez F, Curtis J, Albert R
Int J Chron Obstruct Pulmon Dis. 2008; 3(3):331-50.
PMID: 18990961
PMC: 2629987.
DOI: 10.2147/copd.s681.
Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa.
Skindersoe M, Alhede M, Phipps R, Yang L, Jensen P, Rasmussen T
Antimicrob Agents Chemother. 2008; 52(10):3648-63.
PMID: 18644954
PMC: 2565867.
DOI: 10.1128/AAC.01230-07.
Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.
Hill D, Rose B, Pajkos A, Robinson M, Bye P, Bell S
J Clin Microbiol. 2005; 43(10):5085-90.
PMID: 16207967
PMC: 1248524.
DOI: 10.1128/JCM.43.10.5085-5090.2005.
Effect of erythromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model.
Nagata T, Mukae H, Kadota J, Hayashi T, Fujii T, Kuroki M
Antimicrob Agents Chemother. 2004; 48(6):2251-9.
PMID: 15155229
PMC: 415582.
DOI: 10.1128/AAC.48.6.2251-2259.2004.
Macrolides in the respiratory tract in cystic fibrosis.
Jaffe A, Rosenthal M
J R Soc Med. 2002; 95 Suppl 41:27-31.
PMID: 12216272
PMC: 1308634.
Clinical isolates of Staphylococcus aureus with ribosomal mutations conferring resistance to macrolides.
Prunier A, Malbruny B, Tande D, Picard B, Leclercq R
Antimicrob Agents Chemother. 2002; 46(9):3054-6.
PMID: 12183270
PMC: 127407.
DOI: 10.1128/AAC.46.9.3054-3056.2002.
Effect of telithromycin (HMR 3647) on polymorphonuclear neutrophil killing of Staphylococcus aureus in comparison with roxithromycin.
Vazifeh D, Abdelghaffar H, Labro M
Antimicrob Agents Chemother. 2002; 46(5):1364-74.
PMID: 11959570
PMC: 127134.
DOI: 10.1128/AAC.46.5.1364-1374.2002.